Global Radiopharmaceutical CDMO Market Research Report 2026(Status and Outlook)
A radiopharmaceutical CDMO (Contract Development and Manufacturing Organization) provides specialized services for pharmaceutical companies, research institutions, and other organizations, covering the entire radiopharmaceutical development and production process, or portions of it. CDMOs integrate specialized expertise, advanced technologies, high-end equipment, and specialized personnel in the radiopharmaceutical R&D process. Leveraging their expertise and extensive experience in the field, CDMOs help clients reduce R&D costs, shorten development cycles, and improve efficiency. They also ensure that production processes adhere to stringent quality standards and regulatory requirements, ultimately advancing radiopharmaceuticals from laboratory research to clinical application and commercial production.
The global Radiopharmaceutical CDMO market size was estimated at USD 465.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 7.70% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Radiopharmaceutical CDMO market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Radiopharmaceutical CDMO market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Radiopharmaceutical CDMO market.
Global Radiopharmaceutical CDMO Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Almac
AtomVie
Cardinal Health
Cyclotek
Eckert & Ziegler
Seibersdorf Labor GmbH
Evergreen Theragnostics
Lantheus
Medi-Radiopharma
Minerva Imaging
NorthStar
ROTOP Pharmaka GmbH
Nucleus RadioPharma
PharmaLogic
Market Segmentation (by Type)
R&D CDMO
Production CDMO
Market Segmentation (by Application)
Diagnosis
Treatment
Geographic Segmentation
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Radiopharmaceutical CDMO Market
Overview of the regional outlook of the Radiopharmaceutical CDMO Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Radiopharmaceutical CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Radiopharmaceutical CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Radiopharmaceutical CDMO market size was estimated at USD 465.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 7.70% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Radiopharmaceutical CDMO market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Radiopharmaceutical CDMO market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Radiopharmaceutical CDMO market.
Global Radiopharmaceutical CDMO Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Almac
AtomVie
Cardinal Health
Cyclotek
Eckert & Ziegler
Seibersdorf Labor GmbH
Evergreen Theragnostics
Lantheus
Medi-Radiopharma
Minerva Imaging
NorthStar
ROTOP Pharmaka GmbH
Nucleus RadioPharma
PharmaLogic
Market Segmentation (by Type)
R&D CDMO
Production CDMO
Market Segmentation (by Application)
Diagnosis
Treatment
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Radiopharmaceutical CDMO Market
Overview of the regional outlook of the Radiopharmaceutical CDMO Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Radiopharmaceutical CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Radiopharmaceutical CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Radiopharmaceutical CDMO
1.2 Key Market Segments
1.2.1 Radiopharmaceutical CDMO Segment by Type
1.2.2 Radiopharmaceutical CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 RADIOPHARMACEUTICAL CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 RADIOPHARMACEUTICAL CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Radiopharmaceutical CDMO Product Life Cycle
3.3 Global Radiopharmaceutical CDMO Revenue Market Share by Company (2020-2025)
3.4 Radiopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Headquarters, Areas Served, and Product Types of Major Players
3.6 Radiopharmaceutical CDMO Market Competitive Situation and Trends
3.6.1 Radiopharmaceutical CDMO Market Concentration Rate
3.6.2 Global 5 and 10 Largest Radiopharmaceutical CDMO Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 RADIOPHARMACEUTICAL CDMO VALUE CHAIN ANALYSIS
4.1 Radiopharmaceutical CDMO Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF RADIOPHARMACEUTICAL CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Radiopharmaceutical CDMO Market Porter's Five Forces Analysis
6 RADIOPHARMACEUTICAL CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Radiopharmaceutical CDMO Market by Type (2020-2025)
6.3 Global Radiopharmaceutical CDMO Market Size Growth Rate by Type (2021-2025)
7 RADIOPHARMACEUTICAL CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Radiopharmaceutical CDMO Market Size (M USD) by Application (2020-2025)
7.3 Global Radiopharmaceutical CDMO Market Size Growth Rate by Application (2021-2025)
8 RADIOPHARMACEUTICAL CDMO MARKET SEGMENTATION BY REGION
8.1 Global Radiopharmaceutical CDMO Market Size by Region
8.1.1 Global Radiopharmaceutical CDMO Market Size by Region
8.1.2 Global Radiopharmaceutical CDMO Market Size Market Share by Region
8.2 North America
8.2.1 North America Radiopharmaceutical CDMO Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Radiopharmaceutical CDMO Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Spain
8.4 Asia Pacific
8.4.1 Asia Pacific Radiopharmaceutical CDMO Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Radiopharmaceutical CDMO Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Radiopharmaceutical CDMO Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Almac
9.1.1 Almac Basic Information
9.1.2 Almac Radiopharmaceutical CDMO Product Overview
9.1.3 Almac Radiopharmaceutical CDMO Product Market Performance
9.1.4 Almac SWOT Analysis
9.1.5 Almac Business Overview
9.1.6 Almac Recent Developments
9.2 AtomVie
9.2.1 AtomVie Basic Information
9.2.2 AtomVie Radiopharmaceutical CDMO Product Overview
9.2.3 AtomVie Radiopharmaceutical CDMO Product Market Performance
9.2.4 AtomVie SWOT Analysis
9.2.5 AtomVie Business Overview
9.2.6 AtomVie Recent Developments
9.3 Cardinal Health
9.3.1 Cardinal Health Basic Information
9.3.2 Cardinal Health Radiopharmaceutical CDMO Product Overview
9.3.3 Cardinal Health Radiopharmaceutical CDMO Product Market Performance
9.3.4 Cardinal Health SWOT Analysis
9.3.5 Cardinal Health Business Overview
9.3.6 Cardinal Health Recent Developments
9.4 Cyclotek
9.4.1 Cyclotek Basic Information
9.4.2 Cyclotek Radiopharmaceutical CDMO Product Overview
9.4.3 Cyclotek Radiopharmaceutical CDMO Product Market Performance
9.4.4 Cyclotek Business Overview
9.4.5 Cyclotek Recent Developments
9.5 Eckert and Ziegler
9.5.1 Eckert and Ziegler Basic Information
9.5.2 Eckert and Ziegler Radiopharmaceutical CDMO Product Overview
9.5.3 Eckert and Ziegler Radiopharmaceutical CDMO Product Market Performance
9.5.4 Eckert and Ziegler Business Overview
9.5.5 Eckert and Ziegler Recent Developments
9.6 Seibersdorf Labor GmbH
9.6.1 Seibersdorf Labor GmbH Basic Information
9.6.2 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Overview
9.6.3 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Market Performance
9.6.4 Seibersdorf Labor GmbH Business Overview
9.6.5 Seibersdorf Labor GmbH Recent Developments
9.7 Evergreen Theragnostics
9.7.1 Evergreen Theragnostics Basic Information
9.7.2 Evergreen Theragnostics Radiopharmaceutical CDMO Product Overview
9.7.3 Evergreen Theragnostics Radiopharmaceutical CDMO Product Market Performance
9.7.4 Evergreen Theragnostics Business Overview
9.7.5 Evergreen Theragnostics Recent Developments
9.8 Lantheus
9.8.1 Lantheus Basic Information
9.8.2 Lantheus Radiopharmaceutical CDMO Product Overview
9.8.3 Lantheus Radiopharmaceutical CDMO Product Market Performance
9.8.4 Lantheus Business Overview
9.8.5 Lantheus Recent Developments
9.9 Medi-Radiopharma
9.9.1 Medi-Radiopharma Basic Information
9.9.2 Medi-Radiopharma Radiopharmaceutical CDMO Product Overview
9.9.3 Medi-Radiopharma Radiopharmaceutical CDMO Product Market Performance
9.9.4 Medi-Radiopharma Business Overview
9.9.5 Medi-Radiopharma Recent Developments
9.10 Minerva Imaging
9.10.1 Minerva Imaging Basic Information
9.10.2 Minerva Imaging Radiopharmaceutical CDMO Product Overview
9.10.3 Minerva Imaging Radiopharmaceutical CDMO Product Market Performance
9.10.4 Minerva Imaging Business Overview
9.10.5 Minerva Imaging Recent Developments
9.11 NorthStar
9.11.1 NorthStar Basic Information
9.11.2 NorthStar Radiopharmaceutical CDMO Product Overview
9.11.3 NorthStar Radiopharmaceutical CDMO Product Market Performance
9.11.4 NorthStar Business Overview
9.11.5 NorthStar Recent Developments
9.12 ROTOP Pharmaka GmbH
9.12.1 ROTOP Pharmaka GmbH Basic Information
9.12.2 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Overview
9.12.3 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Market Performance
9.12.4 ROTOP Pharmaka GmbH Business Overview
9.12.5 ROTOP Pharmaka GmbH Recent Developments
9.13 Nucleus RadioPharma
9.13.1 Nucleus RadioPharma Basic Information
9.13.2 Nucleus RadioPharma Radiopharmaceutical CDMO Product Overview
9.13.3 Nucleus RadioPharma Radiopharmaceutical CDMO Product Market Performance
9.13.4 Nucleus RadioPharma Business Overview
9.13.5 Nucleus RadioPharma Recent Developments
9.14 PharmaLogic
9.14.1 PharmaLogic Basic Information
9.14.2 PharmaLogic Radiopharmaceutical CDMO Product Overview
9.14.3 PharmaLogic Radiopharmaceutical CDMO Product Market Performance
9.14.4 PharmaLogic Business Overview
9.14.5 PharmaLogic Recent Developments
10 RADIOPHARMACEUTICAL CDMO MARKET FORECAST BY REGION
10.1 Global Radiopharmaceutical CDMO Market Size Forecast
10.2 Global Radiopharmaceutical CDMO Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Radiopharmaceutical CDMO Market Size Forecast by Country
10.2.3 Asia Pacific Radiopharmaceutical CDMO Market Size Forecast by Region
10.2.4 South America Radiopharmaceutical CDMO Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Sales of Radiopharmaceutical CDMO by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
11.1 Global Radiopharmaceutical CDMO Market Forecast by Type (2026-2035)
11.1.1 Global Radiopharmaceutical CDMO Market Size Forecast by Type (2026-2035)
11.2 Global Radiopharmaceutical CDMO Market Forecast by Application (2026-2035)
11.2.1 Global Radiopharmaceutical CDMO Market Size (M USD) Forecast by Application (2026-2035)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Radiopharmaceutical CDMO
1.2 Key Market Segments
1.2.1 Radiopharmaceutical CDMO Segment by Type
1.2.2 Radiopharmaceutical CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 RADIOPHARMACEUTICAL CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 RADIOPHARMACEUTICAL CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Radiopharmaceutical CDMO Product Life Cycle
3.3 Global Radiopharmaceutical CDMO Revenue Market Share by Company (2020-2025)
3.4 Radiopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Headquarters, Areas Served, and Product Types of Major Players
3.6 Radiopharmaceutical CDMO Market Competitive Situation and Trends
3.6.1 Radiopharmaceutical CDMO Market Concentration Rate
3.6.2 Global 5 and 10 Largest Radiopharmaceutical CDMO Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 RADIOPHARMACEUTICAL CDMO VALUE CHAIN ANALYSIS
4.1 Radiopharmaceutical CDMO Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF RADIOPHARMACEUTICAL CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Radiopharmaceutical CDMO Market Porter's Five Forces Analysis
6 RADIOPHARMACEUTICAL CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Radiopharmaceutical CDMO Market by Type (2020-2025)
6.3 Global Radiopharmaceutical CDMO Market Size Growth Rate by Type (2021-2025)
7 RADIOPHARMACEUTICAL CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Radiopharmaceutical CDMO Market Size (M USD) by Application (2020-2025)
7.3 Global Radiopharmaceutical CDMO Market Size Growth Rate by Application (2021-2025)
8 RADIOPHARMACEUTICAL CDMO MARKET SEGMENTATION BY REGION
8.1 Global Radiopharmaceutical CDMO Market Size by Region
8.1.1 Global Radiopharmaceutical CDMO Market Size by Region
8.1.2 Global Radiopharmaceutical CDMO Market Size Market Share by Region
8.2 North America
8.2.1 North America Radiopharmaceutical CDMO Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Radiopharmaceutical CDMO Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Spain
8.4 Asia Pacific
8.4.1 Asia Pacific Radiopharmaceutical CDMO Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Radiopharmaceutical CDMO Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Radiopharmaceutical CDMO Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Almac
9.1.1 Almac Basic Information
9.1.2 Almac Radiopharmaceutical CDMO Product Overview
9.1.3 Almac Radiopharmaceutical CDMO Product Market Performance
9.1.4 Almac SWOT Analysis
9.1.5 Almac Business Overview
9.1.6 Almac Recent Developments
9.2 AtomVie
9.2.1 AtomVie Basic Information
9.2.2 AtomVie Radiopharmaceutical CDMO Product Overview
9.2.3 AtomVie Radiopharmaceutical CDMO Product Market Performance
9.2.4 AtomVie SWOT Analysis
9.2.5 AtomVie Business Overview
9.2.6 AtomVie Recent Developments
9.3 Cardinal Health
9.3.1 Cardinal Health Basic Information
9.3.2 Cardinal Health Radiopharmaceutical CDMO Product Overview
9.3.3 Cardinal Health Radiopharmaceutical CDMO Product Market Performance
9.3.4 Cardinal Health SWOT Analysis
9.3.5 Cardinal Health Business Overview
9.3.6 Cardinal Health Recent Developments
9.4 Cyclotek
9.4.1 Cyclotek Basic Information
9.4.2 Cyclotek Radiopharmaceutical CDMO Product Overview
9.4.3 Cyclotek Radiopharmaceutical CDMO Product Market Performance
9.4.4 Cyclotek Business Overview
9.4.5 Cyclotek Recent Developments
9.5 Eckert and Ziegler
9.5.1 Eckert and Ziegler Basic Information
9.5.2 Eckert and Ziegler Radiopharmaceutical CDMO Product Overview
9.5.3 Eckert and Ziegler Radiopharmaceutical CDMO Product Market Performance
9.5.4 Eckert and Ziegler Business Overview
9.5.5 Eckert and Ziegler Recent Developments
9.6 Seibersdorf Labor GmbH
9.6.1 Seibersdorf Labor GmbH Basic Information
9.6.2 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Overview
9.6.3 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Market Performance
9.6.4 Seibersdorf Labor GmbH Business Overview
9.6.5 Seibersdorf Labor GmbH Recent Developments
9.7 Evergreen Theragnostics
9.7.1 Evergreen Theragnostics Basic Information
9.7.2 Evergreen Theragnostics Radiopharmaceutical CDMO Product Overview
9.7.3 Evergreen Theragnostics Radiopharmaceutical CDMO Product Market Performance
9.7.4 Evergreen Theragnostics Business Overview
9.7.5 Evergreen Theragnostics Recent Developments
9.8 Lantheus
9.8.1 Lantheus Basic Information
9.8.2 Lantheus Radiopharmaceutical CDMO Product Overview
9.8.3 Lantheus Radiopharmaceutical CDMO Product Market Performance
9.8.4 Lantheus Business Overview
9.8.5 Lantheus Recent Developments
9.9 Medi-Radiopharma
9.9.1 Medi-Radiopharma Basic Information
9.9.2 Medi-Radiopharma Radiopharmaceutical CDMO Product Overview
9.9.3 Medi-Radiopharma Radiopharmaceutical CDMO Product Market Performance
9.9.4 Medi-Radiopharma Business Overview
9.9.5 Medi-Radiopharma Recent Developments
9.10 Minerva Imaging
9.10.1 Minerva Imaging Basic Information
9.10.2 Minerva Imaging Radiopharmaceutical CDMO Product Overview
9.10.3 Minerva Imaging Radiopharmaceutical CDMO Product Market Performance
9.10.4 Minerva Imaging Business Overview
9.10.5 Minerva Imaging Recent Developments
9.11 NorthStar
9.11.1 NorthStar Basic Information
9.11.2 NorthStar Radiopharmaceutical CDMO Product Overview
9.11.3 NorthStar Radiopharmaceutical CDMO Product Market Performance
9.11.4 NorthStar Business Overview
9.11.5 NorthStar Recent Developments
9.12 ROTOP Pharmaka GmbH
9.12.1 ROTOP Pharmaka GmbH Basic Information
9.12.2 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Overview
9.12.3 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Market Performance
9.12.4 ROTOP Pharmaka GmbH Business Overview
9.12.5 ROTOP Pharmaka GmbH Recent Developments
9.13 Nucleus RadioPharma
9.13.1 Nucleus RadioPharma Basic Information
9.13.2 Nucleus RadioPharma Radiopharmaceutical CDMO Product Overview
9.13.3 Nucleus RadioPharma Radiopharmaceutical CDMO Product Market Performance
9.13.4 Nucleus RadioPharma Business Overview
9.13.5 Nucleus RadioPharma Recent Developments
9.14 PharmaLogic
9.14.1 PharmaLogic Basic Information
9.14.2 PharmaLogic Radiopharmaceutical CDMO Product Overview
9.14.3 PharmaLogic Radiopharmaceutical CDMO Product Market Performance
9.14.4 PharmaLogic Business Overview
9.14.5 PharmaLogic Recent Developments
10 RADIOPHARMACEUTICAL CDMO MARKET FORECAST BY REGION
10.1 Global Radiopharmaceutical CDMO Market Size Forecast
10.2 Global Radiopharmaceutical CDMO Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Radiopharmaceutical CDMO Market Size Forecast by Country
10.2.3 Asia Pacific Radiopharmaceutical CDMO Market Size Forecast by Region
10.2.4 South America Radiopharmaceutical CDMO Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Sales of Radiopharmaceutical CDMO by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
11.1 Global Radiopharmaceutical CDMO Market Forecast by Type (2026-2035)
11.1.1 Global Radiopharmaceutical CDMO Market Size Forecast by Type (2026-2035)
11.2 Global Radiopharmaceutical CDMO Market Forecast by Application (2026-2035)
11.2.1 Global Radiopharmaceutical CDMO Market Size (M USD) Forecast by Application (2026-2035)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Radiopharmaceutical CDMO Market Size by Type (M USD)
Table 4. Global Radiopharmaceutical CDMO Market Size by Application
Table 5. Radiopharmaceutical CDMO Market Size Comparison by Region (M USD)
Table 6. Global Radiopharmaceutical CDMO Revenue (M USD) by Company (2020-2025)
Table 7. Global Radiopharmaceutical CDMO Revenue Share by Company (2020-2025)
Table 8. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceutical CDMO as of 2025)
Table 9. Headquarters, Areas Served, and Product Types of Major Players
Table 10. Product Type of Major Players
Table 11. Global Radiopharmaceutical CDMO Company Market Concentration Ratio (CR5 and HHI)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. Radiopharmaceutical CDMO Market Challenges
Table 18. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 19. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 20. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 21. Global Radiopharmaceutical CDMO Market Size by Type (M USD)
Table 22. Global Radiopharmaceutical CDMO Market Size (M USD) by Type (2020-2025)
Table 23. Global Radiopharmaceutical CDMO Market Share by Type (2020-2025)
Table 24. Global Radiopharmaceutical CDMO Market Size Growth Rate by Type (2021-2025)
Table 25. Global Radiopharmaceutical CDMO Market Size by Application
Table 26. Global Radiopharmaceutical CDMO Market Size by Application (2020-2025) & (M USD)
Table 27. Global Radiopharmaceutical CDMO Market Share by Application (2020-2025)
Table 28. Global Radiopharmaceutical CDMO Market Size Growth Rate by Application (2021-2025)
Table 29. Global Radiopharmaceutical CDMO Market Size by Region (2020-2025) & (M USD)
Table 30. Global Radiopharmaceutical CDMO Market Size Market Share by Region (2020-2025)
Table 31. North America Radiopharmaceutical CDMO Market Size by Country (2020-2025) & (M USD)
Table 32. Europe Radiopharmaceutical CDMO Market Size by Country (2020-2025) & (M USD)
Table 33. Asia Pacific Radiopharmaceutical CDMO Market Size by Region (2020-2025) & (M USD)
Table 34. South America Radiopharmaceutical CDMO Market Size by Country (2020-2025) & (M USD)
Table 35. Middle East and Africa Radiopharmaceutical CDMO Market Size by Region (2020-2025) & (M USD)
Table 36. Almac Basic Information
Table 37. Almac Radiopharmaceutical CDMO Product Overview
Table 38. Almac Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 39. Almac SWOT Analysis
Table 40. Almac Business Overview
Table 41. Almac Recent Developments
Table 42. AtomVie Basic Information
Table 43. AtomVie Radiopharmaceutical CDMO Product Overview
Table 44. AtomVie Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 45. AtomVie SWOT Analysis
Table 46. AtomVie Business Overview
Table 47. AtomVie Recent Developments
Table 48. Cardinal Health Basic Information
Table 49. Cardinal Health Radiopharmaceutical CDMO Product Overview
Table 50. Cardinal Health Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 51. Cardinal Health SWOT Analysis
Table 52. Cardinal Health Business Overview
Table 53. Cardinal Health Recent Developments
Table 54. Cyclotek Basic Information
Table 55. Cyclotek Radiopharmaceutical CDMO Product Overview
Table 56. Cyclotek Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 57. Cyclotek Business Overview
Table 58. Cyclotek Recent Developments
Table 59. Eckert and Ziegler Basic Information
Table 60. Eckert and Ziegler Radiopharmaceutical CDMO Product Overview
Table 61. Eckert and Ziegler Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 62. Eckert and Ziegler Business Overview
Table 63. Eckert and Ziegler Recent Developments
Table 64. Seibersdorf Labor GmbH Basic Information
Table 65. Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Overview
Table 66. Seibersdorf Labor GmbH Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 67. Seibersdorf Labor GmbH Business Overview
Table 68. Seibersdorf Labor GmbH Recent Developments
Table 69. Evergreen Theragnostics Basic Information
Table 70. Evergreen Theragnostics Radiopharmaceutical CDMO Product Overview
Table 71. Evergreen Theragnostics Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 72. Evergreen Theragnostics Business Overview
Table 73. Evergreen Theragnostics Recent Developments
Table 74. Lantheus Basic Information
Table 75. Lantheus Radiopharmaceutical CDMO Product Overview
Table 76. Lantheus Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 77. Lantheus Business Overview
Table 78. Lantheus Recent Developments
Table 79. Medi-Radiopharma Basic Information
Table 80. Medi-Radiopharma Radiopharmaceutical CDMO Product Overview
Table 81. Medi-Radiopharma Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 82. Medi-Radiopharma Business Overview
Table 83. Medi-Radiopharma Recent Developments
Table 84. Minerva Imaging Basic Information
Table 85. Minerva Imaging Radiopharmaceutical CDMO Product Overview
Table 86. Minerva Imaging Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 87. Minerva Imaging Business Overview
Table 88. Minerva Imaging Recent Developments
Table 89. NorthStar Basic Information
Table 90. NorthStar Radiopharmaceutical CDMO Product Overview
Table 91. NorthStar Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 92. NorthStar Business Overview
Table 93. NorthStar Recent Developments
Table 94. ROTOP Pharmaka GmbH Basic Information
Table 95. ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Overview
Table 96. ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 97. ROTOP Pharmaka GmbH Business Overview
Table 98. ROTOP Pharmaka GmbH Recent Developments
Table 99. Nucleus RadioPharma Basic Information
Table 100. Nucleus RadioPharma Radiopharmaceutical CDMO Product Overview
Table 101. Nucleus RadioPharma Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 102. Nucleus RadioPharma Business Overview
Table 103. Nucleus RadioPharma Recent Developments
Table 104. PharmaLogic Basic Information
Table 105. PharmaLogic Radiopharmaceutical CDMO Product Overview
Table 106. PharmaLogic Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 107. PharmaLogic Business Overview
Table 108. PharmaLogic Recent Developments
Table 109. Global Radiopharmaceutical CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 110. North America Radiopharmaceutical CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 111. Europe Radiopharmaceutical CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 112. Asia Pacific Radiopharmaceutical CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 113. South America Radiopharmaceutical CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 114. Middle East and Africa Radiopharmaceutical CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 115. Global Radiopharmaceutical CDMO Market Size Forecast by Type (2026-2035) & (M USD)
Table 116. Global Radiopharmaceutical CDMO Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Radiopharmaceutical CDMO Market Size by Type (M USD)
Table 4. Global Radiopharmaceutical CDMO Market Size by Application
Table 5. Radiopharmaceutical CDMO Market Size Comparison by Region (M USD)
Table 6. Global Radiopharmaceutical CDMO Revenue (M USD) by Company (2020-2025)
Table 7. Global Radiopharmaceutical CDMO Revenue Share by Company (2020-2025)
Table 8. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceutical CDMO as of 2025)
Table 9. Headquarters, Areas Served, and Product Types of Major Players
Table 10. Product Type of Major Players
Table 11. Global Radiopharmaceutical CDMO Company Market Concentration Ratio (CR5 and HHI)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. Radiopharmaceutical CDMO Market Challenges
Table 18. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 19. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 20. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 21. Global Radiopharmaceutical CDMO Market Size by Type (M USD)
Table 22. Global Radiopharmaceutical CDMO Market Size (M USD) by Type (2020-2025)
Table 23. Global Radiopharmaceutical CDMO Market Share by Type (2020-2025)
Table 24. Global Radiopharmaceutical CDMO Market Size Growth Rate by Type (2021-2025)
Table 25. Global Radiopharmaceutical CDMO Market Size by Application
Table 26. Global Radiopharmaceutical CDMO Market Size by Application (2020-2025) & (M USD)
Table 27. Global Radiopharmaceutical CDMO Market Share by Application (2020-2025)
Table 28. Global Radiopharmaceutical CDMO Market Size Growth Rate by Application (2021-2025)
Table 29. Global Radiopharmaceutical CDMO Market Size by Region (2020-2025) & (M USD)
Table 30. Global Radiopharmaceutical CDMO Market Size Market Share by Region (2020-2025)
Table 31. North America Radiopharmaceutical CDMO Market Size by Country (2020-2025) & (M USD)
Table 32. Europe Radiopharmaceutical CDMO Market Size by Country (2020-2025) & (M USD)
Table 33. Asia Pacific Radiopharmaceutical CDMO Market Size by Region (2020-2025) & (M USD)
Table 34. South America Radiopharmaceutical CDMO Market Size by Country (2020-2025) & (M USD)
Table 35. Middle East and Africa Radiopharmaceutical CDMO Market Size by Region (2020-2025) & (M USD)
Table 36. Almac Basic Information
Table 37. Almac Radiopharmaceutical CDMO Product Overview
Table 38. Almac Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 39. Almac SWOT Analysis
Table 40. Almac Business Overview
Table 41. Almac Recent Developments
Table 42. AtomVie Basic Information
Table 43. AtomVie Radiopharmaceutical CDMO Product Overview
Table 44. AtomVie Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 45. AtomVie SWOT Analysis
Table 46. AtomVie Business Overview
Table 47. AtomVie Recent Developments
Table 48. Cardinal Health Basic Information
Table 49. Cardinal Health Radiopharmaceutical CDMO Product Overview
Table 50. Cardinal Health Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 51. Cardinal Health SWOT Analysis
Table 52. Cardinal Health Business Overview
Table 53. Cardinal Health Recent Developments
Table 54. Cyclotek Basic Information
Table 55. Cyclotek Radiopharmaceutical CDMO Product Overview
Table 56. Cyclotek Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 57. Cyclotek Business Overview
Table 58. Cyclotek Recent Developments
Table 59. Eckert and Ziegler Basic Information
Table 60. Eckert and Ziegler Radiopharmaceutical CDMO Product Overview
Table 61. Eckert and Ziegler Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 62. Eckert and Ziegler Business Overview
Table 63. Eckert and Ziegler Recent Developments
Table 64. Seibersdorf Labor GmbH Basic Information
Table 65. Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Overview
Table 66. Seibersdorf Labor GmbH Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 67. Seibersdorf Labor GmbH Business Overview
Table 68. Seibersdorf Labor GmbH Recent Developments
Table 69. Evergreen Theragnostics Basic Information
Table 70. Evergreen Theragnostics Radiopharmaceutical CDMO Product Overview
Table 71. Evergreen Theragnostics Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 72. Evergreen Theragnostics Business Overview
Table 73. Evergreen Theragnostics Recent Developments
Table 74. Lantheus Basic Information
Table 75. Lantheus Radiopharmaceutical CDMO Product Overview
Table 76. Lantheus Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 77. Lantheus Business Overview
Table 78. Lantheus Recent Developments
Table 79. Medi-Radiopharma Basic Information
Table 80. Medi-Radiopharma Radiopharmaceutical CDMO Product Overview
Table 81. Medi-Radiopharma Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 82. Medi-Radiopharma Business Overview
Table 83. Medi-Radiopharma Recent Developments
Table 84. Minerva Imaging Basic Information
Table 85. Minerva Imaging Radiopharmaceutical CDMO Product Overview
Table 86. Minerva Imaging Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 87. Minerva Imaging Business Overview
Table 88. Minerva Imaging Recent Developments
Table 89. NorthStar Basic Information
Table 90. NorthStar Radiopharmaceutical CDMO Product Overview
Table 91. NorthStar Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 92. NorthStar Business Overview
Table 93. NorthStar Recent Developments
Table 94. ROTOP Pharmaka GmbH Basic Information
Table 95. ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Overview
Table 96. ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 97. ROTOP Pharmaka GmbH Business Overview
Table 98. ROTOP Pharmaka GmbH Recent Developments
Table 99. Nucleus RadioPharma Basic Information
Table 100. Nucleus RadioPharma Radiopharmaceutical CDMO Product Overview
Table 101. Nucleus RadioPharma Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 102. Nucleus RadioPharma Business Overview
Table 103. Nucleus RadioPharma Recent Developments
Table 104. PharmaLogic Basic Information
Table 105. PharmaLogic Radiopharmaceutical CDMO Product Overview
Table 106. PharmaLogic Radiopharmaceutical CDMO Revenue (M USD) and Gross Margin (2020-2025)
Table 107. PharmaLogic Business Overview
Table 108. PharmaLogic Recent Developments
Table 109. Global Radiopharmaceutical CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 110. North America Radiopharmaceutical CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 111. Europe Radiopharmaceutical CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 112. Asia Pacific Radiopharmaceutical CDMO Market Size Forecast by Region (2026-2035) & (M USD)
Table 113. South America Radiopharmaceutical CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 114. Middle East and Africa Radiopharmaceutical CDMO Market Size Forecast by Country (2026-2035) & (M USD)
Table 115. Global Radiopharmaceutical CDMO Market Size Forecast by Type (2026-2035) & (M USD)
Table 116. Global Radiopharmaceutical CDMO Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Industry Chain of Radiopharmaceutical CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Radiopharmaceutical CDMO Market Size (M USD), 2025-2035
Figure 5. Global Radiopharmaceutical CDMO Market Size (M USD) (2020-2035)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Radiopharmaceutical CDMO Market Size by Country (M USD)
Figure 10. Company Assessment Quadrant
Figure 11. Global Radiopharmaceutical CDMO Product Life Cycle
Figure 12. Global Radiopharmaceutical CDMO Revenue Share by Company in 2025
Figure 13. Radiopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 14. The Global 5 and 10 Largest Players: Market Share by Radiopharmaceutical CDMO Revenue in 2025
Figure 15. Value Chain Map of Radiopharmaceutical CDMO
Figure 16. Global Radiopharmaceutical CDMO Market PEST Analysis
Figure 17. Global Radiopharmaceutical CDMO Market Porter's Five Forces Analysis
Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 19. Global Radiopharmaceutical CDMO Market Share by Type
Figure 20. Market Share of Radiopharmaceutical CDMO by Type (2020-2025)
Figure 21. Global Radiopharmaceutical CDMO Market Size Growth Rate by Type (2021-2025)
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Radiopharmaceutical CDMO Market Share by Application
Figure 24. Global Radiopharmaceutical CDMO Market Share by Application (2020-2025)
Figure 25. Global Radiopharmaceutical CDMO Market Share by Application in 2024
Figure 26. Global Radiopharmaceutical CDMO Market Size Growth Rate by Application (2021-2025)
Figure 27. Global Radiopharmaceutical CDMO Market Size Market Share by Region (2020-2025)
Figure 28. North America Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 29. North America Radiopharmaceutical CDMO Market Size Market Share by Country in 2024
Figure 30. U.S. Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 31. Canada Radiopharmaceutical CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 32. Mexico Radiopharmaceutical CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 33. Europe Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 34. Europe Radiopharmaceutical CDMO Market Share by Country in 2024
Figure 35. Germany Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 36. France Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 37. U.K. Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 38. Italy Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 39. Spain Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 40. Asia Pacific Radiopharmaceutical CDMO Market Size and Growth Rate (M USD)
Figure 41. Asia Pacific Radiopharmaceutical CDMO Market Size Market Share by Region in 2024
Figure 42. China Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 43. Japan Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. South Korea Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 45. India Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. Southeast Asia Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. South America Radiopharmaceutical CDMO Market Size and Growth Rate (M USD)
Figure 48. South America Radiopharmaceutical CDMO Market Size Market Share by Country in 2024
Figure 49. Brazil Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 50. Argentina Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Columbia Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 52. Middle East and Africa Radiopharmaceutical CDMO Market Size and Growth Rate (M USD)
Figure 53. Middle East and Africa Radiopharmaceutical CDMO Market Size Market Share by Region in 2024
Figure 54. Saudi Arabia Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 55. UAE Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. Egypt Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. Nigeria Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. South Africa Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. Global Radiopharmaceutical CDMO Market Size Forecast by Value (2020-2035) & (M USD)
Figure 60. Global Radiopharmaceutical CDMO Market Share Forecast by Type (2026-2035)
Figure 61. Global Radiopharmaceutical CDMO Market Share Forecast by Application (2026-2035)
Figure 1. Industry Chain of Radiopharmaceutical CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Radiopharmaceutical CDMO Market Size (M USD), 2025-2035
Figure 5. Global Radiopharmaceutical CDMO Market Size (M USD) (2020-2035)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Radiopharmaceutical CDMO Market Size by Country (M USD)
Figure 10. Company Assessment Quadrant
Figure 11. Global Radiopharmaceutical CDMO Product Life Cycle
Figure 12. Global Radiopharmaceutical CDMO Revenue Share by Company in 2025
Figure 13. Radiopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 14. The Global 5 and 10 Largest Players: Market Share by Radiopharmaceutical CDMO Revenue in 2025
Figure 15. Value Chain Map of Radiopharmaceutical CDMO
Figure 16. Global Radiopharmaceutical CDMO Market PEST Analysis
Figure 17. Global Radiopharmaceutical CDMO Market Porter's Five Forces Analysis
Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 19. Global Radiopharmaceutical CDMO Market Share by Type
Figure 20. Market Share of Radiopharmaceutical CDMO by Type (2020-2025)
Figure 21. Global Radiopharmaceutical CDMO Market Size Growth Rate by Type (2021-2025)
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Radiopharmaceutical CDMO Market Share by Application
Figure 24. Global Radiopharmaceutical CDMO Market Share by Application (2020-2025)
Figure 25. Global Radiopharmaceutical CDMO Market Share by Application in 2024
Figure 26. Global Radiopharmaceutical CDMO Market Size Growth Rate by Application (2021-2025)
Figure 27. Global Radiopharmaceutical CDMO Market Size Market Share by Region (2020-2025)
Figure 28. North America Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 29. North America Radiopharmaceutical CDMO Market Size Market Share by Country in 2024
Figure 30. U.S. Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 31. Canada Radiopharmaceutical CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 32. Mexico Radiopharmaceutical CDMO Market Size (M USD) and Growth Rate (2020-2025)
Figure 33. Europe Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 34. Europe Radiopharmaceutical CDMO Market Share by Country in 2024
Figure 35. Germany Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 36. France Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 37. U.K. Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 38. Italy Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 39. Spain Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 40. Asia Pacific Radiopharmaceutical CDMO Market Size and Growth Rate (M USD)
Figure 41. Asia Pacific Radiopharmaceutical CDMO Market Size Market Share by Region in 2024
Figure 42. China Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 43. Japan Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. South Korea Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 45. India Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. Southeast Asia Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. South America Radiopharmaceutical CDMO Market Size and Growth Rate (M USD)
Figure 48. South America Radiopharmaceutical CDMO Market Size Market Share by Country in 2024
Figure 49. Brazil Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 50. Argentina Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Columbia Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 52. Middle East and Africa Radiopharmaceutical CDMO Market Size and Growth Rate (M USD)
Figure 53. Middle East and Africa Radiopharmaceutical CDMO Market Size Market Share by Region in 2024
Figure 54. Saudi Arabia Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 55. UAE Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. Egypt Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. Nigeria Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. South Africa Radiopharmaceutical CDMO Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. Global Radiopharmaceutical CDMO Market Size Forecast by Value (2020-2035) & (M USD)
Figure 60. Global Radiopharmaceutical CDMO Market Share Forecast by Type (2026-2035)
Figure 61. Global Radiopharmaceutical CDMO Market Share Forecast by Application (2026-2035)
